Tarsus Pharmaceuticals Inc.
https://www.tarsusrx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Tarsus Pharmaceuticals Inc.
Small But Mitey: Tarsus To Amp Up Strong Xdemvy Launch
Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.
Finance Watch: Investors Support Strategic Shifts At Cullinan, Cidara
Public Company Edition: Cullinan and Cidara shifted their strategic directions and found investors to bring along for the ride. Also, Intra-Cellular closed a post-Phase III $575m follow-on offering and Tarsus accessed up to $200m from Pharmakon.
Finance Watch: Denali, Avidity And Others Chase Big Money Via Private Placements
Public Company Edition: Denali, Crinetics and Ocular Therapeutix grossed $500m, $350m and $325m, respectively, in private placements ahead of data readouts. Also, Viking raised $550m after its positive Phase II obesity data and Abingworth invested $210m in Gilead’s Trodelvy NSCLC trials.
Tarsus Demonstrates Lotilaner’s Potential In Preventing Lyme Disease
Lotilaner, the active ingredient in Tarsus’s Demodex blepharitis drug Xdemvy, showed significant ability to kill ticks in a small Phase IIa study. Analysts call the Lyme program a likely out-licensing opportunity for Tarsus.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Drug Delivery
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice